M
Marcelo Bonomi
Researcher at Ohio State University
Publications - 34
Citations - 774
Marcelo Bonomi is an academic researcher from Ohio State University. The author has contributed to research in topics: Head and neck cancer & Head and neck squamous-cell carcinoma. The author has an hindex of 12, co-authored 34 publications receiving 433 citations. Previous affiliations of Marcelo Bonomi include The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Lillian L. Siu,Caroline Even,Ricard Mesia,Éva Remenár,Amaury Daste,Jean Pierre Delord,Jürgen Krauss,Nabil F. Saba,Lisle Nabell,Neal Ready,Irene Brana,Nuria Kotecki,Dan P. Zandberg,Jill Gilbert,Hisham Mehanna,Marcelo Bonomi,Anthony Jarkowski,Anthony Jarkowski,Giovanni Melillo,Jon Armstrong,Sophie Wildsmith,Jérôme Fayette +21 more
TL;DR: In patients with R/M HNSCC and low or no PD-L1 tumor cell expression, all 3 regimens exhibited a manageable toxicity profile and Durvalumab and durvalumAB + tremelimumab resulted in clinical benefit, with minimal observed difference between the two.
Journal ArticleDOI
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
Carryn M. Anderson,Christopher M. Lee,Deborah P. Saunders,Amarinthia Curtis,Neal Dunlap,Chaitali Singh Nangia,Arielle S. Lee,Sharon M. Gordon,Philip Kovoor,Roberto Arevalo-Araujo,Voichita Bar-Ad,Abhinand V. Peddada,Kyle Colvett,Douglas C. Miller,Anshu K. Jain,James Wheeler,Dukagjin Blakaj,Marcelo Bonomi,Sanjiv S. Agarwala,Madhur Garg,Francis P. Worden,Jon Holmlund,Jeffrey Mark Brill,Matthew Downs,Stephen T. Sonis,Sanford Katz,John M. Buatti +26 more
TL;DR: GC4419 at a dose of 90 mg produced a significant, clinically meaningful reduction of SOM duration, incidence, and severity with acceptable safety, and a phase III trial has begun.
Journal ArticleDOI
Effect of Age on Survival of Clinical Stage I Non-Small-Cell Lung Cancer
TL;DR: In unresected patients, lung cancer is the major source of mortality, even in the oldest age groups, suggesting that elderly patients with stage I lung cancer should receive aggressive surgical management when possible.
Journal ArticleDOI
Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data.
TL;DR: Many promising new biological targets currently undergoing investigation to ameliorate or help prevent the toxicity of OM in HNC are highlighted along with the pathobiology of OM, clinical course, prevention, and management measures.
Journal ArticleDOI
Time to Surgery and Survival in Head and Neck Cancer.
Chandler J. Rygalski,Songzhu Zhao,Antoine Eskander,Kevin Y. Zhan,Edmund A. Mroz,Guy Brock,Dustin A. Silverman,Dukagjin Blakaj,Marcelo Bonomi,Ricardo L. Carrau,Matthew O. Old,James W. Rocco,Nolan B. Seim,Sidharth V. Puram,Stephen Y. Kang +14 more
TL;DR: Increasing TTS is an independent predictor of survival for patients with HNSCC and should be performed within 67 days after diagnosis to achieve optimal survival outcomes.